# Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma

> **NCT04506320** · — · COMPLETED · sponsor: **Gruppo Italiano Trapianto di Midollo Osseo** · enrollment: 202 (actual)

## Conditions studied

- Multiple Myeloma
- Stem Cell Transplant

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04506320
- **Lead sponsor:** Gruppo Italiano Trapianto di Midollo Osseo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-17
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2023-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04506320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04506320, "Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04506320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*